Previous 10 | Next 10 |
Primary neutrophil engraftment of trem-cel achieved in all seven patients treated to date All three patients receiving multiple Mylotarg™ doses exhibited hematologic protection , further validating Vor Bio’s approach Conference call today, N...
Vor Biopharma Inc. (VOR) is expected to report $-0.46 for Q3 2023
2023-11-07 18:03:47 ET More on Vor Biopharma Seeking Alpha’s Quant Rating on Vor Biopharma Historical earnings data for Vor Biopharma Financial information for Vor Biopharma For further details see: Vor Biopharma GAAP EPS of -$0.49 misses by $0.02
Next trem-cel (VOR33) clinical data update expected by Relapse After Transplant and Cellular Therapy (HSCT 2 ) Conference Nov 10-11 Three oral abstracts and two poster presentations accepted at ASH 2023 Dec 9-12 CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Vor B...
Three oral and two poster presentations accepted by ASH Company to host call featuring Sarah K. Tasian, MD, Associate Professor of Pediatrics at the University of Pennsylvania School of Medicine and Chief of the Hematologic Malignancies Program in the Division of Oncology at Children's ...
CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of October 1, 2023, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 19,250 sha...
2023-08-11 09:56:13 ET Vor Biopharma press release ( NASDAQ: VOR ): Q2 GAAP EPS of -$0.45 beats by $0.03 . Cash, cash equivalents and marketable securities were $186.9 million as of June 30, 2023, which is projected to fund operations into the first quarter of 2025. ...
Next trem-cel clinical data update expected by year-end 2023 VCAR33 ALLO IND cleared by U.S. FDA; Rapidly activating sites toward study initiation Secured non-exclusive license to Cas9 gene-edited HSCs CAMBRIDGE, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE...
CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, will host in-person 1x1 investor meetings at the 2023 Wedbush PacGrow Healthcare Conference. Wedbush PacGrow Healthcare Conference 1x1 Investor Meetings: Au...
2023-07-18 17:26:50 ET Gainers: Ribbon Communications ( NASDAQ: RBBN ) +7% . Terns Pharmaceuticals ( TERN ) +3% . Arrival ( ARVL ) +3% . EyePoint Pharmaceuticals ( EYPT ) +3% . Lyra Therapeutics ( LYRA ) +3% . ...
News, Short Squeeze, Breakout and More Instantly...
Vor Biopharma Inc. Company Name:
VOR Stock Symbol:
NASDAQ Market:
On-track for trem-cel and VCAR33 ALLO clinical updates in the second half of 2024 Trem-cel trial expanded to include patients with myelodysplastic syndromes (MDS); Mylotarg™ dosing has advanced to the third cohort CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWI...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced t...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of Directors. Dr. Namouni currently serves as President of Research & Development at Blueprint M...